Pesquisar





Pesquisar





Mercados
/
Ações
/
nasdaq-abbv
/

AbbVie Inc

ABBV

Adicionar à lista de desejos

217.670USD

-0.960-0.44%

Fechamento 05/29, 16:00（ET）Cotações atrasadas em 15 min

384.56BValor de mercado

107.14P/L TTM



AbbVie Inc

217.670

-0.960-0.44%

Visão Geral Serviços Financeiros Discussões Análises Empresa

Visão Geral

Serviços Financeiros

Discussões

Análises

Empresa

Mais detalhes de AbbVie Inc Empresa

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

Informações de AbbVie Inc



Código da empresaABBV

Nome da EmpresaAbbVie Inc

Data de listagemJan 02, 2013

CEOMichael (Robert A)

Número de funcionários55000

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 02

Endereço1 N Waukegan Rd

CidadeNORTH CHICAGO

Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE

PaísUnited States of America

Código postal60064

Telefone18479327900

Sitehttps://www.abbvie.com/

Código da empresaABBV

Data de listagemJan 02, 2013

CEOMichael (Robert A)

Executivos da empresa AbbVie Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

204.37K

+0.05%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

135.75K

+0.82%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

55.37K

+5.41%

Mr. Edward J. (Ed) Rapp

Independent Director

45.96K

+2.43%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

39.58K

+2.82%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

Mr. Frederick H. (Rick) Waddell

Independent Director

30.08K

+3.72%

Ms. Melody B. Meyer

Independent Director

17.62K

+6.35%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-346.66%

Mr. Thomas J. (Tom) Falk

Independent Director

5.32K

+21.01%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

204.37K

+0.05%

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

135.75K

+0.82%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

55.37K

+5.41%

Mr. Edward J. (Ed) Rapp

Independent Director

45.96K

+2.43%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

39.58K

+2.82%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

17.56B

28.71%

Immunology-RINVOQ

8.30B

13.58%

Immunology-HUMIRA

4.54B

7.42%

Neuroscience-Botox Therapeutic

3.77B

6.16%

Neuroscience-Vraylar

3.62B

5.92%

Outro

23.36B

38.20%

Por RegiãoUSD

Nome

Receita

Proporção

United States

44.49B

72.75%

International

13.04B

21.32%

All other countries

2.63B

4.30%

Germany

1.74B

2.84%

Japan

1.27B

2.08%

Outro

-2.01B

-3.29%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

17.56B

28.71%

Immunology-RINVOQ

8.30B

13.58%

Immunology-HUMIRA

4.54B

7.42%

Neuroscience-Botox Therapeutic

3.77B

6.16%

Neuroscience-Vraylar

3.62B

5.92%

Outro

23.36B

38.20%

Distribuição de ações

Atualizado em: dom, 10 de mai

Investidores

Tipos de investidores

Investidores

Proporção

Vanguard Capital Management, LLC

6.50%

BlackRock Institutional Trust Company, N.A.

5.38%

State Street Investment Management (US)

4.58%

Vanguard Portfolio Management, LLC

2.80%

Geode Capital Management, L.L.C.

2.53%

Outro

78.21%

Investidores

Proporção

Vanguard Capital Management, LLC

6.50%

BlackRock Institutional Trust Company, N.A.

5.38%

State Street Investment Management (US)

4.58%

Vanguard Portfolio Management, LLC

2.80%

Geode Capital Management, L.L.C.

2.53%

Outro

78.21%

Tipos de investidores

Investidores

Proporção

Investment Advisor

45.09%

Investment Advisor/Hedge Fund

21.63%

Research Firm

3.14%

Bank and Trust

2.36%

Pension Fund

2.28%

Sovereign Wealth Fund

1.54%

Insurance Company

0.67%

Hedge Fund

0.46%

Family Office

0.22%

Outro

22.62%

Participação acionária institucional



Atualizado em: qua, 1 de abr

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2026Q1

5703

1.36B

77.09%

+26.64M

2025Q4

5311

1.33B

74.86%

+1.37M

2025Q3

5386

1.32B

74.95%

+8.86M

2025Q2

5326

1.32B

74.78%

+2.41M

2025Q1

5334

1.32B

74.15%

+3.84M

2024Q4

5267

1.31B

73.92%

+9.35M

2024Q3

4970

1.30B

74.13%

-1.24M

2024Q2

4907

1.30B

73.33%

+14.47M

2024Q1

4916

1.28B

72.48%

+1.37M

2023Q4

4861

1.27B

72.12%

+10.24M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

BlackRock Institutional Trust Company, N.A.

95.07M

5.38%

+2.29M

+2.47%

Dec 31, 2025

State Street Investment Management (US)

80.94M

4.58%

+1.12M

+1.40%

Dec 31, 2025

Geode Capital Management, L.L.C.

44.63M

2.52%

+4.19M

+10.36%

Dec 31, 2025

JP Morgan Asset Management

34.79M

1.97%

-1.63M

-4.49%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

25.67M

1.45%

+2.57M

+11.11%

Dec 31, 2025

Capital Research Global Investors

25.41M

1.44%

+177.37K

+0.70%

Dec 31, 2025

Charles Schwab Investment Management, Inc.

25.17M

1.42%

-788.26K

-3.04%

Dec 31, 2025

Fidelity Management & Research Company LLC

21.48M

1.21%

+1.53M

+7.67%

Dec 31, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

VanEck Pharmaceutical ETF

9.64%

First Trust NASDAQ Pharmaceuticals ETF

8.05%

Health Care Select Sector SPDR Fund

7.89%

Proshares Ultra Health Care

7.62%

iShares U.S. Healthcare ETF

7.57%

JPMorgan Healthcare Leaders ETF

6.87%

Simplify Health Care ETF

6.73%

Fidelity MSCI Health Care Index ETF

6.5%

Harbor Health Care ETF

6.18%

iShares Core High Dividend ETF

5.9%

Ver Mais

VanEck Pharmaceutical ETF

Proporção9.64%

First Trust NASDAQ Pharmaceuticals ETF

Proporção8.05%

Health Care Select Sector SPDR Fund

Proporção7.89%

Proshares Ultra Health Care

Proporção7.62%

iShares U.S. Healthcare ETF

Proporção7.57%

JPMorgan Healthcare Leaders ETF

Proporção6.87%

Simplify Health Care ETF

Proporção6.73%

Fidelity MSCI Health Care Index ETF

Proporção6.5%

Harbor Health Care ETF

Proporção6.18%

iShares Core High Dividend ETF

Proporção5.9%

Dividendo



Um total de 40.87B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Feb 19, 2026

ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option

Apr 15, 2026

May 15, 2026

Apr 15, 2026

Oct 31, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.73 paid on Feb 17, 2026 going ex on Jan 16, 2026 with reinvestment option

Jan 16, 2026

Feb 17, 2026

Jan 16, 2026

Sep 05, 2025

ABBV.NB Final Cash Dividend of gross USD 1.64 paid on Nov 14, 2025 going ex on Oct 15, 2025 with reinvestment option

Oct 15, 2025

Nov 14, 2025

Oct 15, 2025

Jun 20, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option

Jul 15, 2025

Aug 15, 2025

Jul 15, 2025

Feb 13, 2025

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option

Apr 15, 2025

May 15, 2025

Apr 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Ver Mais

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados

KeyAI

